Form 4: AVADEL COO Exercises Options in Alkermes Acquisition

Avadel Pharmaceuticals' Chief Operating Officer, Susan Rodriguez, disposed of 300,000 stock options as part of the company's acquisition by Alkermes plc.

Summary

• Susan Rodriguez, Chief Operating Officer of Avadel Pharmaceuticals PLC, reported the disposition of 300,000 stock options.
• This transaction occurred on February 12, 2026, coinciding with the effective time of Avadel's acquisition by Alkermes plc through a scheme of arrangement.
• Each outstanding option was canceled and exchanged for a cash payment and a non-transferable contingent value right (CVR).
• The cash payment is calculated as the total number of shares subject to the option (300,000) multiplied by the difference between the acquisition price ($21.00) and the option's exercise price ($9.59).
• The CVR entitles holders to a potential additional cash payment of $1.50 per share, contingent upon the achievement of certain milestones.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive event for the option holder, as it monetizes their equity stake at a premium to the exercise price, with potential for further upside via a CVR, reflecting a successful acquisition for Avadel shareholders.

Positives

• The acquisition by Alkermes plc provides a clear exit strategy and liquidity for Avadel's option holders.
• Option holders receive an immediate cash payment based on the difference between the acquisition price ($21.00) and the exercise price ($9.59).
• A contingent value right (CVR) offers potential for an additional $1.50 per share upon the achievement of specific milestones.

Negatives

• The disposition of options means the Chief Operating Officer no longer holds direct equity upside in Avadel Pharmaceuticals PLC.
• The contingent value right (CVR) is non-transferable, limiting flexibility for holders.
• The additional $1.50 payment from the CVR is contingent and not guaranteed, depending on future milestone achievements.

Risks

• The contingent value right (CVR) payment of $1.50 per share is not guaranteed and depends on the achievement of unspecified milestones.

Future Outlook

The filing indicates the completion of Avadel Pharmaceuticals' acquisition by Alkermes plc, suggesting Avadel will no longer operate as an independent publicly traded entity. The future performance of the CVR depends on the achievement of specific, undisclosed milestones.

Industry Context

StockSavvy.ai notes that this acquisition by Alkermes plc highlights ongoing consolidation within the pharmaceutical sector, particularly for companies with promising drug pipelines or market positions. Such transactions often aim to leverage synergies, expand product portfolios, and enhance market share for the acquiring entity.

Stakeholder Impact

• Shareholders: The acquisition by Alkermes plc implies a cash payout for Avadel shareholders (though this filing focuses on options).
• Option Holders (like Susan Rodriguez): Receive cash and a CVR, providing liquidity and potential future upside.
• Employees: Implied integration into Alkermes plc, with potential changes in roles or structure.

Next Steps

• Achievement of unspecified milestones for the contingent value right (CVR) payment.

Key Dates

Keywords

Avadel Pharmaceuticals, Alkermes, Acquisition, Merger, Stock Options, Form 4, Insider Transaction, Contingent Value Right, AVDL